RxDoctor Payments DataLook up a doctor →

Ramoun Jones, MD

Interventional Pain Medicine · Phoenix, AZNPI 1508898602

Payments from drug & device makers

$51,309in general payments, 2019–2025

Across 842 payments — averaging $60.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Painteq LLC$14K
  • Abbott$7K
  • Foundation Fusion Solutions, LLC$6K
  • Aurora Spine, Inc.$6K
  • Boston Scientific$4K
  • Vertos Medical, Inc.$4K
  • plus $10K from 29 others

What the payments were for

  • Consulting fees$19,17637%
  • Travel & lodging$1,6943%
  • Food & beverage$27,01053%
  • Education$3,3286%
  • Entertainment$1010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,309 in reported general payments places this provider in the 80th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$248,388
Medicare patients
322
Services billed
7,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen284$7,786
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen208$7,531
Gabapentin281$3,463
Pregabalin71$2,786
Methocarbamol87$1,728
Tramadol Hcl127$1,187
Tizanidine Hcl101$1,168
Oxycodone Hcl85$1,137
Mupirocin111$994
Cyclobenzaprine Hcl80$922
Cephalexin90$873
Morphine Sulfate30$859
Duloxetine Hcl48$621
Hydromorphone Hcl29$315
Clindamycin Hcl18$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAMorphine Sulfate$42$85930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →